PTU - Polskie Towarzystwo Urologiczne
list of articles:

Immunogenotherapy of prostate cancer
Article published in Urologia Polska 2003/56/2.

authors

Jerzy Trojan 3, Piotr Kopiński 3, Tomasz Drewa 2, Jolanta Powierska-Czarny 1, Joanna Pacholska 1, Piotr Jarocki 3, Zbigniew Wolski 2
1 Katedra i Zakład Genoterapii Akademii Medycznej w Bydgoszczy
Kierownik katedry: prof- AMB dr hab. Jerzy Trojan
2 Katedra i Klinika Urologu Akademii Medycznej w Bydgoszczy
Kierownik katedry: prof. AMB dr hab. Zbigniew Wolski
3 Pracownia Genoterapii Collegium Medicum UJ w Krakowie
Kierownik pracowni: prof. AMB dr hab. Jerzy Trojan

keywords

prostate, prostate cancer, gene therapy, oligonucleotides

summary

In the paper we summarize basic data on gene therapy and immunogenotherapy applied in prostate tumour, as well as the prospects of treatment with antisense techniques directed against insulin-like growth factor (IGF-I) expression in tumour cells.
Insulin-like growth factor-I (IGF-I) participates in tumourigenesis of many organs. It seems to be of great importance in prostate cancer by contributing in lesions initiation, progression and/or dissemination. IGF-I expression in tumour cells can be inhibited by transfection with vectors encoding antisense sequences for IGF-I gene transcript or with the use of triple-helix techniques. The latter seems to be more effective and it consists of complimentary oligonucleotide ligation to the promoter gene region. Previously this method was used in cerebral glioma and hepatoma genotherapy resulting in satisfactory and promising observations. Transfected tumour cells presented overexpression of superficial MHC class I antigens and costimulatory molecules of B7 group which succeeded in inducing the immune response.
The authors of the study, from the Department of Urology and the Department of Genotherapy, the Ludwik Rydygier Medical University in Bydgoszcz, have recently undertaken clinical trials on application of triple-helix in prostate cancer\'s immunogenotherapy.

references

  1. 1. Baserga R: Oncogenes and the strategy of growth factors. Cell 1994; 79:927-930.
  2. 2. Rubin R. Baserga R: Insulin-like growth factor-l receptor. Its role in cellproliferation, apoptosis. and tumorigenicity. Lab Invest 1995: 73: 311-331.
  3. 3. Bondy CA, Werner H, Roberts CT Jr, LeRoith D: Cellular pattern of insu-lin-like growth factor-l (IGF-lj and type I IGF receptor gene expression in early organogenesis: comparison with IGF-U gene expression. Mol Endocrinol 1990:4(9): 1386-1398.
  4. 4. Zapf J. Froesch C S: Pathophysiological and clinical aspects of the insulin-Uke growth factors. HormRes 1986: 24 (2-3): 160-165.
  5. 5. Karasik A. Menczer J. Pariente C. Kanety H: Insidin-like growth factor--1 (IGF-I) and IGF-binding protein-2 are increased in cyst fluids ofepithe-lialovarian cancer. J Clin Endocrinol Metab 1994; 78 (2): 271-276.
  6. 6. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M. Grimley C,Battey J, Mulshine JL, Cutlitta F: Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 1996; 271 (19): 11477-11483.
  7. 7. Reeve JG, Brinkman A, Hughes S, Mitchell J. Schwander J, BleehenNM: Expression of insulin like growth factor (IGF) and IGF-binding protein genes in human lung tumor cell lines. J Natl Cancer Inst 1992; 84 (8): 628-634.
  8. 8. Trojan J, Johnson TR, Rudin SD. Ilan J. Tykocinski ML, Han J: Treat-ment andprevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993; 259 (5091): 94-97.
  9. 9. Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Dwyer ST:High-risk colorectal adenomas and serum insulin-like growth factors. Br J Surg 2001; 88(1): 107-113.
  10. 10. Pollak M: Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000: 36(10): 1224-1228.
  11. 11. Trojan J, Johnson TR, Rudin SD, Blossey BK, Kelley KM, Shevelev A, Abdul-Karim FW, Anthony DD, Tykocinski ML, Dan J: Gene therapy of murine teratocarcinoma: separate functions for insulin-like growth factors I and fl in immunogenicity and differentiation. Proc Natl Acad Sci USA 1994; 91 (13): 6088-6092.
  12. 12. Trojan J: From neoplastic neural development to gene therapy of brain tumors -IGP-I antisense and triple helix approaches. Biotechnologia 2002, in press.
  13. 13. Upegui-Gonzalez LC. Ly A. Sierzega M. Jarocki P. Trojan L, Due HT. Pan Y. Shevelev A. Henin D, Anthony D, Nowak W. Popiela T and Trojan J: IGF-I triple helix strategy in hepatoma treatment. Hepatoga-stroenterology 2001:48 (39): 660-666.
  14. 14. Izant JG. Weintraub H: Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. Science 1985; 229 (4711): 345-352.
  15. 15. Ly A, Due HT, Kalamarides M. Trojan LA, Pan Y. Shevelev A, Francois JC. Noel T, Kane A, Henin D, Anthony DD. Trojan J: Human glioma cells transformed by IGF-I triple helix technology show immune and apoptolic characteristics determining cell selection for gene therapy of glioblastoma. Mol Pathol 2001: 54 (4): 230-239.
  16. 16. Han VKM, Hill DJ: The Insulin-like growth factors: Structure and biological functions. Oxford 1992. Oxford University Press, Ed. Shofield P. N.: 178-219.
  17. 17. Kue PF, Daaka Y: Essential role for G proteins in prostate cancer cell growth and signaling. J Urol 2000; 164 (6): 2162-2167.
  18. 18. Long L. Rubin R, Baserga R. Brodt P: Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 1995; 55(5): 1006-1009.
  19. 19. Baserga R, Resnicoff M, DAmbrosio C, Valentinis B: The role of the IGF-I receptor in apoptosis. VitamHorm 1997; 53; 65-98.
  20. 20. Ellouk-Achard S. Djenabi S. De Oliveira GA, Desauty G. Due HT, Zo-hair M, Trojan J, Claude JR, Sarasin A, Lafarge-Frayssinet C: Induction of apoptosis in rat hepatocarcinoma cells by expression oflGF-I anti-sense c-DNA. J Hepatol 1998; 29 (5): 807-818.
  21. 21. Iwamura M, Ishibe M, Sluss PM. Cockett AT: Characterization of insulin-like growth factor 1 binding sites in human bladder cancer cell lines. Urol Res 1993. 21(1): 27-32.
  22. 22. Roberts CT Jr: Control of insulin-like growth factor (IGF) action by regulation ofIGF-I receptor expression. EndocrJ 1996; 43 Suppl: 49-55.
  23. 23. Djavan B, Waldert M, Seitz C, MarbergerM: Insulin-iilce growth factors and prostate cancer. World J Urol 2001; 19 (4): 225-233.
  24. 24. Figueroa JA, Lee AV, Jackson JG, Yee D: Proliferation of cultured human prostate cancer ceUs is inhibited by insulin-like growth factor (IGF) bindingprotein-1: evidence fur an IGF-Uautocrine growth loop. J Clin Endocrinol Metab 1995; 80(12): 3476-3482.
  25. 25. Damon SE, Plymate SR. Carroll JM. Sprenger CC. Dechsukhum C. Ware JL. Roberts CT Jr: Transcriptional regulation of insulin-like growth factor-1 receptor gene expression in prostate cancer cells. Endocrinology 2001: 142(1): 21-27.
  26. 26. Kwon ED, Hurwitz AA, Foster BA. Madias C, Feldhaus AL. Crcen-berg NM. Burg MB. Allison JP: Manipulation off cell costimuhtory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997: 94 (I 5): 8099-9103.
  27. 27. Harrington KJ. Spitzweg C. Bateman AR, Morris JC. Vile RG: Gem therapy for prostate, cancer: current status and future prospects. J Urol 2001; 166(4): 1220-1233.
  28. 28. Eder JP, KanlolTPW. Roper K, Xu GK. Bublcy GJ, Boyden J. Gritz L. Mascara G, Oh WK. Arlen P, Tsang KY. Panicali D, Schlom J. Kufe DW: A phase I. trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000: 6. 1632-1638.
  29. 29. Steiner MS, Anthony CT. Lu Y, Holt JT: Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum Gene Tlier 1998: 20.9 (5); 747-755.
  30. 30. Miyake II, Hara I, Kamidono S. Gleave ME: Novel therapeutic strategy for advanced prostate, cancer using antisense oligodeoxynuiieotides targeting anti-apoptotic genes uprcgulated after androgen withdrawal to delay androgen-independent progression and enhance dieinosensitivity. Int J Urol 2001; 8 (7): 337-349.
  31. 31. Sanda MG, Ayyagari SR. Jaffee EM, Epstein JI, Clift SI.. Cohen LK. Dranoff G. Pardoll DM, Mulligan RC, Simons JW: Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994: 151 (3): 622-628.
  32. 32. Simmons SJ, Tjoa BA, Rogers M. Elgamal A, Kenny GM, Ragde H. Troychak MJ, Boynton AL. Murphy GP: GM-CSF as a systemic adjuvant in a phase U prostate cancer vaccine trial. Prostate 1999: 39 (4): 291-297.
  33. 33. Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR. Gansba-cher B, Gilboa E: Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994; 54 (7): 1760-1765.
  34. 34. Belldegrun A. Bander Nil, Lerner SR Wood DP Pantuek AJ: Society of Urologie Oncology Biotechnology Forum: new approaches and targets for advanced prostate\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'cancer.] Urol 2001; 166 (4): 1316-1321.
  35. 35. Tjoa BA. Simmons Sf, Bowes VA, Ragde II, Rogers M, Elgamal A. Kenny GM, Cobb OE. Ireton RC, Troychak MJ. SalgallerML, Boynton AL. Murphy GP: Evaluation of phase 1/11 clinical trials in prostate cancer with dendritic cells andPSMA peptides. Prostate 1998:36(1): 39-44.
  36. 36. Pielrzkowski 7„ Mulholland G. Gomella L. Jameson BA, Wernicke D. Baserga R: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 7. Cancer Res 1993: 53 (5): 1102-1 106.

correspondence

Jerzy Trojan
Katedra i Zakfad Genoterapu AMB
ul. M. Skłodowskiej-Curie 9
85~094 Bydgoszcz